Advanced Biomarker Research Framework for the Biological Definition and Classification of Neurological Diseases Using Multivariate Data Analysis Methods

Thursday, September 25, 2025

10 a.m. EDT | 4 p.m. CEST 


Biomarkers have been revolutionizing neurological disease classification, diagnosis, and monitoring. Genetic sequencing and high-dimensional multi-omics panels are powerful tools to provide a comprehensive outlook of biomarker changes. However, challenges remain in defining clinically meaningful biomarkers and potential confounding factors, as well as contextualizing biomarker role within a broader diagnostic/classification framework, incorporating patient characteristics and assessments.

This presentation delves into the use of multivariate statistical techniques, including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), to analyze biomarker profiles and identify influential pathobiological signatures, unveiling the relationship with clinical features and outcomes. Such enhanced understanding has the potential to pave the way towards precision medicine in neurological diseases.

 

What You Will Learn:

  1. Find out how OPLS-DA was used to maximize the identification of biomarker signatures that significantly influence patient classification and staging
  2. Understand how MVDA can assess the relationship between biomarkers and outcomes while identifying relevant clinical variables associated with class discrimination
  3. Discover how multivariate discriminant analysis can be employed to evaluate the diagnostic accuracy of combinations of biomarkers

Please Complete the Form

Complete Form to Register

Presenter

This webinar is presented by Stefania Mondello, Professor of Biostatistics and Research Methodology at the University of Messina (Italy). Stefania is a physician-scientist (MD, PhD, MPH) with a sub-specialty in critical care medicine and more than 15 years of experience in clinical and biomarker research and advanced statistical analysis methods. The ultimate goal of her research is to develop actionable brain injury biomarkers which can guide clinical decision-making. The pioneering work she has been leading has contributed to the development of new biomarkers of brain injury being used in clinical studies and settings around the world.